{"analyses":[{"ciLowerLimit":"10.53","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"32.95","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.001","paramType":"Cochran-Mantel- Haenszel chi-square test","paramValue":"21.74","statisticalMethod":"Cochran-Mantel-Haenszel"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"37.58"},{"groupId":"OG001","value":"15.79"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"157"},{"groupId":"OG001","value":"76"}],"units":"Participants"}],"description":"MMR at 96 weeks was defined as the percentage of participants with MMR at 96 weeks. MMR was defined as a ≥ 3.0 log reduction in BCR-ABL1 transcripts compared to the standardized baseline equivalent to ≤ 0.1% BCR-ABL1/ABL% by international scale (IS) as measured by RQ-PCR.","groups":[{"description":"Participants randomized to asciminib 40mg BID","id":"OG000","title":"Asciminib"},{"description":"Participants randomized to bosutinib 500mg QD","id":"OG001","title":"Bosutinib"}],"paramType":"NUMBER","populationDescription":"Full Analysis Set (FAS): The FAS comprised of all randomized participants.","reportingStatus":"POSTED","timeFrame":"96 Weeks","title":"Major Molecular Response (MMR) Rate at 96 Weeks (Key Secondary Endpoint)","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}